Faster diagnostic results for COVID-19 and bacterial co-infections with our SARS-CoV-2 suite of products
We offer a broad menu of infectious disease molecular diagnostic solutions for critically ill, hospitalized patients, including the Unyvero multiplex Hospitalized Pneumonia (HPN) panel, a SARS-CoV-2 RT PCR Test and PULB PCR-Compatible Universal Lysis Buffer (RUO), providing rapid responses to the COVID-19 pandemic. Our products help deliver faster diagnostic results to enable optimized treatment for these patients.
Patients infected with the SARS-CoV-2 coronavirus often suffer from bacterial pneumonia co-infections, which lead to higher mortality rates and more severe outcomes in COVID-19 patients. Our Unyvero HPN Hospitalized Pneumonia application offers fast diagnostic results in 4 to 5 hours, capable of identifying 29 pathogens and 19 resistance markers with only a few minutes of hands on time.
PULB PCR-Compatible Universal Lysis Buffer (RUO)*
Save money and time when testing for SARS-CoV-2 coronavirus
With our PULB buffer, coronavirus testing becomes faster and cheaper. PULB addresses a key bottleneck in today’s SARS-CoV-2 testing set-up.
Nucleic acid extraction is a major bottleneck in current COVID-19 testing, in terms of turn-around, logistics, component availability and costs, which delays or completely precludes COVID-19 diagnostics in many settings. The PULB – PCR-Compatible Universal Lysis Buffer (RUO) enables the PCR-compatible release of nucleic acids directly from biological samples in just one step without the need for further components such as extraction columns. The isolation of viral RNA is an essential step for pathogen isolation and detection. PULB can be used in combination with virtually all real-time nucleic acid PCR tests.
Get cheaper results when testing for SARS-CoV-2
- Saves labor, reagent cost and reduces total test time
- PCR-Compatible Universal Lysis Buffer
- Suitable for RNA & DNA preparation, directly from native patient sample
- Works with viruses and bacteria, directly from lysed sample to PCR assay
- Eliminates column purification; improves nucleic acid yield
BGI CE-marked COVID-19 RT-PCR Test kit for detecting the SARS-CoV-2 coronavirus
The BGI 2019-nCoV RT-qPCR kit enables diagnostic laboratories to perform SARS-CoV-2 testing of nasopharyngeal swabs and bronchoalveolar lavage fluid from patients suspected of suffering from COVID-19. The test kit is compatible with standard methods for extracting the nucleic acid of the virus from the sample and can be performed using standard real-time PCR instruments such as the ABI 7500 series instrument. The test kit contains all necessary reagents and controls to test up to 48 patients in just a few hours and enables fast diagnostic results for COVID-19.
- Real-Time Fluorescent RT-PCR kit for detection of SARS-CoV-2
- FDA-cleared, CE-marked, NMPA approved
- Kit with 50 reactions, including 2 Controls pos/neg, for 48 patient samples
- Validated to be used in conjunction with the Qiagen QIAamp Virus RNA Mini Kit and ABI 7500 instrument
- Sample types: Throat swabs, bronchoalveolar lavage (BAL)
- Detection limit: 100 copies/ml
Hospitalized Pneumonia (HPN) Unyvero Cartridge for faster diagnostic results for bacterial coinfections of COVID-19 coronavirus patients
Our multiplex PCR application for bacterial pneumonia offers results for 48 pathogens and resistance markers with high clinical relevance for severe bacterial pneumonia infections. Results are available in 4 to 5 hours with minimal hands-on time of just a few minutes which leads to faster diagnostic outcomes and improved patient treatment. Bacterial coinfections in COVID-19 pneumonia can lead to more severe disease progression and higher mortality rates in these patients. Our HPN cartridge provides an important diagnostic tool in this setting.